Answer:
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors. It is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. Bivalirudin inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. It has a quick onset of action and a short half-life, without binding to plasma proteins (other than thrombin) or red blood cells.
Explanation:
Genomics..Data mining contributes to the field of genomics..
